The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

LISOFYLLINE     1-(5-hydroxyhexyl)-3,7- dimethyl-purine-2,6...

Synonyms: lysofylline, SureCN680306, AG-L-65879, AC1L1NOB, CTK8F1540, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of BL 194


High impact information on BL 194

  • Thus, LSF blocked IL-12-enhanced IFN-gamma production in anti-CD3-stimulated T cells and prevented IL-12-mediated repression of the transcription factor GATA-3 [6].
  • We have previously shown that lisofylline (LSF) inhibits murine Th1-mediated disease in vivo by blocking IL-12-induced differentiation of Th1 cells [6].
  • These findings were extended to show that LSF also inhibits IL-12-dependent responses in human T cells [6].
  • We examined the effect of a novel anti-inflammatory drug, lisofylline (LSF), on EAE induced either by injection of mouse spinal cord homogenate or following transfer of myelin basic protein-reactive T cells [1].
  • METHODS: Lisofylline was added to isolated NOD islets in vitro, with or without IL-1 beta [2].

Chemical compound and disease context of BL 194


Biological context of BL 194


Anatomical context of BL 194


Associations of BL 194 with other chemical compounds


Gene context of BL 194


Analytical, diagnostic and therapeutic context of BL 194


  1. Prevention of experimental allergic encephalomyelitis via inhibition of IL-12 signaling and IL-12-mediated Th1 differentiation: an effect of the novel anti-inflammatory drug lisofylline. Bright, J.J., Du, C., Coon, M., Sriram, S., Klaus, S.J. J. Immunol. (1998) [Pubmed]
  2. The anti-inflammatory compound lisofylline prevents Type I diabetes in non-obese diabetic mice. Yang, Z.D., Chen, M., Wu, R., McDuffie, M., Nadler, J.L. Diabetologia (2002) [Pubmed]
  3. The effects of post-treatment with lisofylline, a phosphatidic acid generation inhibitor, on sepsis-induced acute lung injury in pigs. Hasegawa, N., Oka, Y., Nakayama, M., Berry, G.J., Bursten, S., Rice, G., Raffin, T.A. Am. J. Respir. Crit. Care Med. (1997) [Pubmed]
  4. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma. Margolin, K., Atkins, M., Sparano, J., Sosman, J., Weiss, G., Lotze, M., Doroshow, J., Mier, J., O'Boyle, K., Fisher, R., Campbell, E., Rubin, J., Federighi, D., Bursten, S. Clin. Cancer Res. (1997) [Pubmed]
  5. Treatment of newly diagnosed AML, RAEB-t or RAEB with lisofylline or placebo in addition to chemotherapy. Estey, E.H., Thall, P.F., Reed, P., Kantarjian, H., Beran, M., Pierce, S., Keating, M.J. Leukemia (1999) [Pubmed]
  6. Selective pharmacologic inhibition of murine and human IL-12-dependent Th1 differentiation and IL-12 signaling. Coon, M.E., Diegel, M., Leshinsky, N., Klaus, S.J. J. Immunol. (1999) [Pubmed]
  7. Effects of heparin and lisofylline on pulmonary function after smoke inhalation injury in an ovine model. Tasaki, O., Mozingo, D.W., Dubick, M.A., Goodwin, C.W., Yantis, L.D., Pruitt, B.A. Crit. Care Med. (2002) [Pubmed]
  8. Lisofylline suppresses ex vivo release by murine spleen cells of hematopoietic inhibitors induced by cancer chemotherapeutic agents. de Vries, P., Singer, J.W. Exp. Hematol. (2000) [Pubmed]
  9. Lisofylline decreases white cell adhesiveness and improves survival after experimental hemorrhagic shock. Waxman, K., Daughters, K., Aswani, S., Rice, G. Crit. Care Med. (1996) [Pubmed]
  10. Preferential radiosensitization of G1 checkpoint-deficient cells by methylxanthines. Russell, K.J., Wiens, L.W., Demers, G.W., Galloway, D.A., Le, T., Rice, G.C., Bianco, J.A., Singer, J.W., Groudine, M. Int. J. Radiat. Oncol. Biol. Phys. (1996) [Pubmed]
  11. Lisofylline causes rapid and prolonged suppression of serum levels of free fatty acids. Bursten, S.L., Federighi, D., Wald, J., Meengs, B., Spickler, W., Nudelman, E. J. Pharmacol. Exp. Ther. (1998) [Pubmed]
  12. Effect in supralethally irradiated rats of granulocyte colony-stimulating factor and lisofylline on hematopoietic reconstitution by syngeneic bone marrow or whole organ passenger leukocytes. Murase, N., Ye, Q., Sakamoto, T., Terakura, M., Demetris, A.J., Thomson, A.W., Rao, A., Starzl, T.E. Transplantation (1997) [Pubmed]
  13. Lisofylline, a novel antiinflammatory agent, protects pancreatic beta-cells from proinflammatory cytokine damage by promoting mitochondrial metabolism. Chen, M., Yang, Z., Wu, R., Nadler, J.L. Endocrinology (2002) [Pubmed]
  14. Activation of the 12-lipoxygenase and signal transducer and activator of transcription pathway during neointima formation in a model of the metabolic syndrome. Pei, H., Gu, J., Thimmalapura, P.R., Mison, A., Nadler, J.L. Am. J. Physiol. Endocrinol. Metab. (2006) [Pubmed]
  15. Metabolism of lisofylline and pentoxifylline in human liver microsomes and cytosol. Lillibridge, J.A., Kalhorn, T.F., Slattery, J.T. Drug Metab. Dispos. (1996) [Pubmed]
  16. Pharmacological therapy for acute respiratory distress syndrome. Jain, R., DalNogare, A. Mayo Clin. Proc. (2006) [Pubmed]
  17. Antioxidant and radical scavenging properties of 8-oxo derivatives of xanthine drugs pentoxifylline and lisofylline. Bhat, V.B., Madyastha, K.M. Biochem. Biophys. Res. Commun. (2001) [Pubmed]
  18. Lisofylline sensitizes p53 mutant human ovarian carcinoma cells to the cytotoxic effects of cis-diamminedichloroplatinum (II). Husain, A., Rosales, N., Schwartz, G.K., Spriggs, D.R. Gynecol. Oncol. (1998) [Pubmed]
  19. Cytochrome P450 isozymes involved in lisofylline metabolism to pentoxifylline in human liver microsomes. Lee, S.H., Slattery, J.T. Drug Metab. Dispos. (1997) [Pubmed]
  20. Potential role for phosphatidic acid in mediating the inflammatory responses to TNF alpha and IL-1 beta. Bursten, S., Weeks, R., West, J., Le, T., Wilson, T., Porubek, D., Bianco, J.A., Singer, J.W., Rice, G.C. Circ. Shock (1994) [Pubmed]
  21. CYP3A4-mediated oxidation of lisofylline to lisofylline 4,5-diol in human liver microsomes. Shin, H.S., Slattery, J.T. Journal of pharmaceutical sciences. (1998) [Pubmed]
  22. Effects of lisofylline on hyperoxia-induced lung injury. George, C.L., Fantuzzi, G., Bursten, S., Leer, L., Abraham, E. Am. J. Physiol. (1999) [Pubmed]
  23. The novel anti-inflammatory agent lisofylline prevents autoimmune diabetic recurrence after islet transplantation. Yang, Z., Chen, M., Ellett, J.D., Fialkow, L.B., Carter, J.D., Nadler, J.L. Transplantation (2004) [Pubmed]
  24. Intestinal mucosal dysfunction and infection during remission-induction therapy for acute myeloid leukaemia. Bow, E.J., Meddings, J.B. Leukemia (2006) [Pubmed]
  25. Lisofylline, an inhibitor of unsaturated phosphatidic acid generation, ameliorates interleukin-1 beta-induced dysfunction in cultured rat islets. Bleich, D., Chen, S., Bursten, S.L., Nadler, J.L. Endocrinology (1996) [Pubmed]
  26. A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study Group. List, A.F., Maziarz, R., Stiff, P., Jansen, J., Liesveld, J., Andrews, F., Schuster, M., Wolff, S., Litzow, M., Karanes, C., Dahlberg, S., Kirkhart, B., Bianco, J.A., Singer, J.W. Bone Marrow Transplant. (2000) [Pubmed]
WikiGenes - Universities